Cargando…

Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases

There are several antibody therapeutics in preclinical and clinical development, industry-wide, for the treatment of central nervous system (CNS) disorders. Due to the limited permeability of antibodies across brain barriers, the quantitative understanding of antibody exposure in the CNS is importan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bloomingdale, Peter, Bakshi, Suruchi, Maass, Christian, van Maanen, Eline, Pichardo-Almarza, Cesar, Yadav, Daniela Bumbaca, van der Graaf, Piet, Mehrotra, Nitin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604880/ https://www.ncbi.nlm.nih.gov/pubmed/34378151 http://dx.doi.org/10.1007/s10928-021-09776-7

Ejemplares similares

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs
por: Stevens, Jasper, et al.
Publicado: (2009)

Model reduction in mathematical pharmacology: Integration, reduction and linking of PBPK and systems biology models
por: Snowden, Thomas J., et al.
Publicado: (2018)

A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability
por: Chung, Douglas, et al.
Publicado: (2023)

Mathematical Biology Models of Parkinson's Disease
por: Bakshi, Suruchi, et al.
Publicado: (2018)

Understanding the Effect of Statins and Patient Adherence in Atherosclerosis via a Quantitative Systems Pharmacology Model Using a Novel, Hybrid, and Multi-Scale Approach
por: Pichardo-Almarza, Cesar, et al.
Publicado: (2017)

From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine
por: Pichardo-Almarza, Cesar, et al.
Publicado: (2016)

Salvaging CNS Clinical Trials Halted Due to COVID‐19
por: Geerts, Hugo, et al.
Publicado: (2020)

Incorporating Target Shedding Into a Minimal PBPK–TMDD Model for Monoclonal Antibodies
por: Li, L, et al.
Publicado: (2014)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics
por: Parmar, Keyur R., et al.
Publicado: (2023)

Development of a Patient-Specific Multi-Scale Model to Understand Atherosclerosis and Calcification Locations: Comparison with In vivo Data in an Aortic Dissection
por: Alimohammadi, Mona, et al.
Publicado: (2016)

A multiscale modelling approach to understand atherosclerosis formation: A patient-specific case study in the aortic bifurcation
por: Alimohammadi, Mona, et al.
Publicado: (2017)

Towards personalised management of atherosclerosis via computational models in vascular clinics: technology based on patient-specific simulation approach
por: Díaz-Zuccarini, Vanessa, et al.
Publicado: (2014)

Pharmacokinetic Characterization and Tissue Distribution of Fusion Protein Therapeutics by Orthogonal Bioanalytical Assays and Minimal PBPK Modeling
por: Sugimoto, Hiroshi, et al.
Publicado: (2020)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models
por: Mavroudis, Panteleimon D., et al.
Publicado: (2019)

Editorial: Exploring Maternal-Fetal Pharmacology Through PBPK Modeling Approaches
por: Dallmann, André, et al.
Publicado: (2022)

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
por: Eldar-Finkelman, Hagit, et al.
Publicado: (2011)

Multiscale, patient-specific computational fluid dynamics models predict formation of neointimal hyperplasia in saphenous vein grafts
por: Donadoni, Francesca, et al.
Publicado: (2020)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option
por: Clausznitzer, Diana, et al.
Publicado: (2018)

A Workflow for Global Sensitivity Analysis of PBPK Models
por: McNally, Kevin, et al.
Publicado: (2011)

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements
por: Yang, Yi, et al.
Publicado: (2022)

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
por: Ferreira, Abigail, et al.
Publicado: (2021)

Patient-Specific, Multi-Scale Modeling of Neointimal Hyperplasia in Vein Grafts
por: Donadoni, Francesca, et al.
Publicado: (2017)

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023)

Using a Systems Pharmacology Approach to Study the Effect of Statins on the Early Stage of Atherosclerosis in Humans
por: Pichardo–Almarza, C, et al.
Publicado: (2015)

Conceptually plausible Bayesian inference in interval timing
por: Maaß, Sarah C., et al.
Publicado: (2021)

The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells
por: Saleh, Mohammed A.A., et al.
Publicado: (2023)

PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016)

Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
por: Jamei, Masoud
Publicado: (2020)

Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?
por: Ibarra, Manuel, et al.
Publicado: (2020)

PBPK model reporting template for chemical risk assessment applications
por: Tan, Yu-Mei, et al.
Publicado: (2020)

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

PKQuest: PBPK modeling of highly lipid soluble and extracellular solutes
por: Levitt, David G.
Publicado: (2018)

Complex Mixtures: Array PBPK Modeling of Jet Fuel Components
por: Sterner, Teresa R., et al.
Publicado: (2023)

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
por: Ayyar, Vivaswath S., et al.
Publicado: (2022)

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
por: Rubino, Christopher M, et al.
Publicado: (2018)

Memantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis
por: Pichardo-Rojas, Diego, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o675v62s47gs08h0tghjvs0o6k